Prosecution Insights
Last updated: November 11, 2026
Application No. 18/720,165

PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE

Non-Final OA §101§112
Filed
Jun 14, 2024
Priority
Dec 14, 2021 — EU 21214560.1 +1 more
Examiner
LEE, CHIHYI NMN
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Studiengesellschaft Kohle gGmbH
OA Round
1 (Non-Final)
34%
Grant Probability
At Risk
1-2
OA Rounds
1y 2m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants only 34% of cases
34%
Career Allowance Rate
30 granted / 88 resolved
-25.9% vs TC avg
Strong +62% interview lift
Without
With
+61.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
67 currently pending
Career history
172
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
16.0%
-24.0% vs TC avg
§112
31.0%
-9.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 88 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of the following species: Compound 5 as the elected species of compound of Formula (I); [Cp*RuCl]4 as the elected species of a Ru-catalyst/Formula (III); Compound 7 having the structure of: PNG media_image1.png 77 108 media_image1.png Greyscale (wherein R1 and R2 form a six-membered ring, R3 and R4 are methyl, and R5 and R6 are hydrogen) as the elected species of Formula (II); 1,2 DCE (dichloroethane) as the elected species of organic solvent in the reply filed on July 21, 2026 is acknowledged. Please note Applicant elects Compound 5 but did not recite a chemical structure nor a chemical name of said compound, said compound is reasonably construed in view of page 18 , line 1 -10 of the specification, to refer to Compound 5, 1-(3-Methoxy-3-methylbut-1-yn-1-yl)cyclohex-1-ene, having the structure of: PNG media_image2.png 94 128 media_image2.png Greyscale . The traversal is on the grounds that applicant asserts “the claimed process of claim 1 would, in any review of the prior art encompass a broader subject matter than that required in the 'election', and that such would also cause no undue burden upon the Office”. This is not found persuasive, because applicant appears to mischaracterize the basis for restriction practice under PCT Rule 13. It is respectfully noted that search burden is not a restriction requirement for PCT international phase application; Instead, the restriction requirements use the “unity of invention” to evaluate whether the groups of invention and the groups of species share the same or corresponding technical feature. It is also respectfully noted that the claim 1 applicant relies upon is now canceled. As stated in the previous Office Action, the technical feature shared among the groups of species lacks a priori. Given that applicant did not particularly point out the supposed error with respect to the unity of invention set forth in the restriction requirement under the PCT Rule, the requirement is still deemed proper and is therefore made FINAL. Please note applicant fails to include which claims reads on the elected species; However, upon careful consideration, the Examiner determine that claims 5-7 are drawn to a compound of Formula (I) non-elected. Claims 5-7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on July 21, 2026. Status of Claims Claims 2-7 and 9-14 are pending. Claims 5-7 are withdrawn. Claims 2-4 and 9-14 are under examination in accordance with the elected species. Priority The instant application 18/720,165 filed on June 14, 2024 is a 371 of PCT/EP2022/083715 filed on November 29, 2022, which claims priority to, and the benefits of Foreign Application No. EP21214560.1 filed on December 14, 2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 6/14/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Specification The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant’s use. Arrangement of the Specification As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase “Not Applicable” should follow the section heading: (a) TITLE OF THE INVENTION. (b) CROSS-REFERENCE TO RELATED APPLICATIONS. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A READ-ONLY OPTICAL DISC, AS A TEXT FILE OR AN XML FILE VIA THE PATENT ELECTRONIC SYSTEM. (f) STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR. (g) BACKGROUND OF THE INVENTION. (1) Field of the Invention. (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98. (h) BRIEF SUMMARY OF THE INVENTION. (i) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S). (j) DETAILED DESCRIPTION OF THE INVENTION. (k) CLAIM OR CLAIMS (commencing on a separate sheet). (l) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet). (m) SEQUENCE LISTING. (See MPEP § 2422.03 and 37 CFR 1.821 - 1.825). A “Sequence Listing” is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required “Sequence Listing” is not submitted as an electronic document either on read-only optical disc or as a text file via the patent electronic system. Content of Specification (a) TITLE OF THE INVENTION: See 37 CFR 1.72(a) and MPEP § 606. The title of the invention should be placed at the top of the first page of the specification unless the title is provided in an application data sheet. The title of the invention should be brief but technically accurate and descriptive, preferably from two to seven words. It may not contain more than 500 characters. (b) CROSS-REFERENCES TO RELATED APPLICATIONS: See 37 CFR 1.78 and MPEP § 211 et seq. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT: See MPEP § 310. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. See 37 CFR 1.71(g). (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A READ-ONLY OPTICAL DISC, AS A TEXT FILE OR AN XML FILE VIA THE PATENT ELECTRONIC SYSTEM: The specification is required to include an incorporation-by-reference of electronic documents that are to become part of the permanent United States Patent and Trademark Office records in the file of a patent application. See 37 CFR 1.77(b)(5) and MPEP § 608.05. See also the Legal Framework for Patent Electronic System posted on the USPTO website (https://www.uspto.gov/sites/default/files/documents/2019LegalFrameworkPES.pdf) and MPEP § 502.05 (f) STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR. See 35 U.S.C. 102(b) and 37 CFR 1.77. (g) BACKGROUND OF THE INVENTION: See MPEP § 608.01(c). The specification should set forth the Background of the Invention in two parts: (1) Field of the Invention: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled “Technical Field.” (2) Description of the Related Art including information disclosed under 37 CFR 1.97 and 37 CFR 1.98: A description of the related art known to the applicant and including, if applicable, references to specific related art and problems involved in the prior art which are solved by the applicant’s invention. This item may also be titled “Background Art.” (h) BRIEF SUMMARY OF THE INVENTION: See MPEP § 608.01(d). A brief summary or general statement of the invention as set forth in 37 CFR 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention. (i) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S): See MPEP § 608.01(f). A reference to and brief description of the drawing(s) as set forth in 37 CFR 1.74. (j) DETAILED DESCRIPTION OF THE INVENTION: See MPEP § 608.01(g). A description of the preferred embodiment(s) of the invention as required in 37 CFR 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described, and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication which adequately describes the subject matter. (k) CLAIM OR CLAIMS: See 37 CFR 1.75 and MPEP § 608.01(m). The claim or claims must commence on a separate sheet or electronic page (37 CFR 1.52(b)(3)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate subcombinations or related steps. See 37 CFR 1.75 and MPEP 608.01(i) - (p). (l) ABSTRACT OF THE DISCLOSURE: See 37 CFR 1.72 (b) and MPEP § 608.01(b). The abstract is a brief narrative of the disclosure as a whole, as concise as the disclosure permits, in a single paragraph preferably not exceeding 150 words, commencing on a separate sheet following the claims. In an international application which has entered the national stage (37 CFR 1.491(b)), the applicant need not submit an abstract commencing on a separate sheet if an abstract was published with the international application under PCT Article 21. The abstract that appears on the cover page of the pamphlet published by the International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the abstract that will be used by the USPTO. See MPEP § 1893.03(e). (m) SEQUENCE LISTING: See 37 CFR 1.821 - 1.825 and MPEP §§ 2421 - 2431. The requirement for a sequence listing applies to all sequences disclosed in a given application, whether the sequences are claimed or not. See MPEP § 2422.01. The disclosure is objected to because of the following informalities: The disclosure fails to follow the proper arrangements noted above, omitting the sections that should be included (e.g., ”CROSS-REFERENCE TO RELATED APPLICATIONS”), and repeatedly misses a section heading (e.g., “(g) BACKGROUND OF THE INVENTION” and “(1) Field of the Invention” section headings are missing). Page 9, last paragraph: the term “aryl” is missing a left double quotation mark (i.e., “), and that appears to be a typographical error. The examples provided within the parenthesis are intended to demonstrate, at a minimum, the issues identified and should not be construed as encompassing each and every issue in its entirety. Applicant is required to carefully check the entire specification for any, and all issues noted above. Appropriate correction is required. Claim Interpretation The claimed term “alkyl”, when reasonably construed in view of the special definition provides in page 9, 2nd paragraph of the specification shown below: PNG media_image3.png 67 650 media_image3.png Greyscale , is taken to include straight-chain, cyclic or branched saturated hydrocarbon group. Claim Objections Claims 2-7 and 9-14 are objected to because of the following informalities: Regarding claims 2-7 and 9-13, the claim missing proper article, e.g., --the--, before the noun “process” and that appears to be grammatically incorrect. Regarding claim 2, the term “from” is repeated twice in the same sentence, e.g., “the Ru-catalyst is selected from from COD”, and the second recitation should be deleted as it appears to be typographical error. the coordinating conjunction “or” in the phrase of “(C1 to C12 alkyl)CN, or (C1 to C12 alkyl)2O)” should be deleted, because the coordinating conjunction “and” is already recited before the final item in the list of alternatives; and therefore, including another coordinating conjunction “or” within the same list is improper. Regarding claim 5, the recitation of “Formula (I) )” contains duplicated, right parenthesis symbol and that appears to be a typographical error. Regarding claim 14, the recitation of “group selected from…or…” uses an improper coordinating conjunction “or” and should the coordinating conjunction –and— before the final item in the list of alternatives. For example, the recitation should read –group selected from…and…--, so it is clear that the group is choosing from a collective group that contains each and every alternatives positively recited. Appropriate correction is required. Claim Rejections - 35 USC § 101/112 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 2-4 and 9-14 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility. Instant claims 14 is drawn to a process genus for C-H insertion by gem-hydrogenation of an internal alkyne comprising hydrogenating a compound of Formula (I) in the presence of a Ru-catalyst in an organic solvent, whereby a compound of Formula (II) is obtained. Although instant claim 14 does not expressly recite the final product, i.e., a compound of Formula (I), is “building blocks”, the specification disclosed the claimed processes provide spirocyclic and bridged ring systems that can serve as building blocks for medicinal chemistry and chemical biology as its utility (see e.g., p. 38, “conclusion” of the specification); however, such disclosure is insufficient to establish the practical utility of the compound produced by the chemical process instantly claimed. Attention is direct to Brenner v. Manson, 383 U.S. 519, 528-536, 48 USPQ 689, 695 (1966), where the court held that the practical utility of the compound produced by a chemical process is an essential element in establishing a prima facie case for the patentability of the process. Particularly, the court established the requirement that a chemical process be useful is not satisfied by a showing that the compound yielded belongs to a class of compounds which scientists are screening for possible uses nor is the utility requirement for chemical processes satisfied by a showing that the process works, i.e., yields the intended product. The court ruled that "a process patent in the chemical field, which has not been developed and pointed to the degree of specific utility, creates a monopoly of knowledge which should be granted only if clearly commanded by the statute. Until the process claim has been reduced to production of a product shown to be useful, the metes and bounds of that monopoly are not capable of precise delineation”. In other words, under Brenner v. Manson, 383 U.S. 519 (1966), simply proving that a chemical process works to produce the intended compound does not, by itself, establish a practical utility for the claimed process. In the present case, a general statement that the products obtained from the claimed process are “building blocks for medicinal chemistry and chemical biology” (see e.g., p. 38, “conclusion” of the specification) is not helpful in determining if applicant has identified a specific and substantial utility for the invention. Such disclosure identifies no particular downstream use and that use is would not have been apparent to a skilled artisan. Therefore, the claimed process fails to establish a specific, practical and substantial utility for the resulting product as required for patentability. Claims 2-4 and 9-14 are also rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph. Specifically, because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 2 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Instant claim 2 recites “further common readily dissociating dative ligands known in the art”, and that promises a broad genus of common readily dissociating dative ligands. However, there is insufficient written basis for common readily dissociating dative ligands in the specification. The specification does not identify the further common readily dissociating dative ligands known in the art as broadly encompassed by the claim, chemical formula, synthetic preparation, or representative examples thereof. The mere boiler plate reference to “further common readily dissociating dative ligands known in the art” does not provide adequate blaze marks to the vast genus encompassed by the claims; thus, the specification does not reasonably convey to one of ordinary skill in the art that Applicant was in possession of the full scope of the claimed genus. Claims 2-4 and 9-14 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for obtaining certain compound of Formula (II) by hydrogenating certain compound of Formula (I) in the presence of specific Ru-catalyst in certain organic solvent, does not reasonably provide enablement for the entire scope of obtaining a compound of Formula (II) by hydrogenating a compound of Formula (II) in the presence of a Ru-catalyst in an organic solvent. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. In this case, instant claim 14 is drawn to a process for C-H insertion by gem-hydrogenation of an internal alkyne comprising hydrogenating a compound of Formula (I) in the presence of a Ru-catalyst in an organic solvent, whereby a compound of Formula (II) is obtained. Accordingly, the enablement inquiry under 35 U.S.C. 112(a) encompasses whether the specification teaches one of ordinary skill in the art how to use or make the full scope of the claimed process without undue experimentation. The subject matter considered enabled for preparing certain compound of formula (II) by hydrogenating certain compound of Formula (I) in the presence of specific Ru-catalyst in certain organic solvent as disclosed in the representative procedures (see page 29-37 of the specification); However, the rejection is directed to the substantially broader unexplored portions of the process genus. I. Legal Standard The enablement requirement of 35 U.S.C. 112(a) requires the specification to teach a person of ordinary skill in the art how to make and use the claimed invention without undue experimentation. Attention is directed to In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and, (8) the quantity of experimentation necessary. No single factor is dispositive, and the factors must be weighed together. MPEP 2164.01(a). The specification need not exemplify every embodiment within the claim(s). Nevertheless, the disclosure must enable the full scope of the invention as defined by its claims. The more extensive the claimed genus and the less predictable the art, more guidance and representative disclosure may be required. MPEP 2164.08. The existence of some inoperative embodiments does not necessarily render a claim non-enabled. The relevant is whether the specification and the knowledge in the art permit the skilled artisan to distinguish operative from inoperative embodiments with no more than reasonable experimentation. Claims encompassing significant number of inoperative embodiments may be non- enabled when the specification does not identify the operative embodiments and extensive experimentation would be required to determine which embodiments work. MPEP 2164.08 (b). Here, the specification identifies a method for turning certain internal alkynes (compound of Formula (I)) into cyclic molecules by adding hydrogen atoms, thereby arriving at compound of Formula (II). The issue is therefore not simply based upon whether the chemical structures of formula (I) and (II) can necessarily be drawn or whether every individual compound would be synthetically inaccessible. The issue is whether a skilled artisan, using the disclosure and the knowledge existing in the art, could make and use the full claimed genus without conducting an undue experimentation and discovery. II. Detailed analysis under Wands factors Factor 1: Breadth of the claims This factor weighs strongly against enablement of the full scope. In the present case, instant amended claim 1 recites a method encompasses hydrogenating a compound of Formula (I) PNG media_image4.png 135 140 media_image4.png Greyscale in the presence of a Ru-catalyst in an organic solvent, whereby a compound of formula (II) PNG media_image5.png 108 139 media_image5.png Greyscale is obtained. The claims permit multiple independently selected structural variables within Formula (I) and Formula (II) and a variety of Ru-catalysts and organic solvents to perform the gem-hydrogenation reaction. Particularly, Formula (I) and Formula (II) permits variable in at least: R1 and R2 each independently selected from hydrogen, Si(C1 to C12 alkyl)3, C(=O)-O-(C1 to C12 alkyl), (C1 to C12)alkyl, hetero(C1 to C12)alkyl, or may be joined together to form a ring system via the alkyl or the heteroalkyl; R3 and R4 each independently selected from OSi(C1 to C12 alkyl)3, C(=O)-O-(C1 to C12 alkyl), (C1 to C12)alkyl, hetero(C1 to C12)alkyl, or may be joined together to form a ring system via the alkyl or the heteroalkyl; R5 and R6 are each independently selected from hydrogen, deuterium, (C1 to C12)alkyl, C=O-(C1 to C12)alkyl, C(=O)-O-(C1 to C12 alkyl), NRN1RN2, hetero(C1 to C12)alkyl, or may be joined together to form a ring system via the alkyl or the heteroalkyl; R2 and R3 may be joined together to form a ring system; R4 and R5 may be joined together to form a ring system; and Q is substituted or unsubstituted carbon, oxygen or NRN. The claim also permits independently selected structural variables within Formula (III) to arrive at Ru-catalyst, and these structural variables includes: Rcp1 to Rcp5, each independently selected from branched or linear alkyl, cycloalkyl, ORH, NRH2, C(=O)-O-(C1 to C12 alkyl), or C(=O)N(C1 to C12 alkyl)2; X is selected from Cl, Br, I, OTf, BF4, PF6, or O(C1 to C12 alkyl); and L is a ligand, or a di-, tri- or tetramer thereof. In addition, the specification provides special definitions to the claimed term, including the term “alkyl” (see page 9, 2nd paragraph of the specification) to include straight-chain, cyclic or branched saturated hydrocarbon group. The breadth of the claims is substantial. The breadth of the claims does not arise merely from a long list of individual disclosed compounds of Formula (I), (II) and (III), and organic solvents; Rather, the claims permit independent selection and combination of multiple broad Markush variables. The resulting genus includes substantial different ring systems (such as bridge and spiro rings), and different steric, electronic, conformational, aromatic, non-aromatic and hydrogen-bonding profiles. The disclosed examples do not proportionately sample that multidimensional scope. Instead, the examples cluster around hydrogenating particular 1,3-enyne-containing compounds in the presence of [Cp*RuCl]4 in 1,2-dichloroethane for obtaining particular substituted rings. Factor 2: Nature of the invention This factor weighs against enablement of the full scope. The invention pertains to a ruthenium-catalyzed gem-hydrogenation method that uses hydrogen gas to add both hydrogens to one of the same acetylenic C-atom of formula (I) in an organic solvent, and then generating a vinyl carbene complex as a reactive intermediate that is capable of inserting into primary, secondary, or tertiary C-H bonds, thereby obtaining a compound of Formula (II). Thus, the nature of the invention therefore depends on whether the compound of formula (I) in the presence of a Ru-catalyst in an organic solvent can satisfy the method genus of obtaining a compound of Formula (II). Such gem-hydrogenation reaction depends not merely upon the presence of a nominal eyne to obtain vinyl-substituted 5-membered ring scaffold, but upon the combined influence of: the identity and attachment position of each substituent; ring size and topology; heteroatom identity and placement; hydrogen-bond donor and acceptor geometry; steric fit within the binding pocket; conformational orientation; electronic characteristics; the identity of the Ru-catalyst; and the identity and polarity of organic solvent. The common eyne core may provide a structural starting point for gem-hydrogenation reaction, but the claimed invention is not limited to a narrow series in which only a predictably interchangeable terminal group is varied, nor limited to a narrow combination of Ru-catalyst and organic solvent. The claims permit extensive alterations adjacent to and extending from the core at multiple positions, permit the formation of bridge, spiro, and fused ring systems, extensive alternations adjacent to and extending from the ruthenium core, The nature of the invention is therefore one in which operative reaction depends upon experimentally determined factors, rather than merely upon the ability to draw the synthetic schemes with compound satisfying the generic formula. Factor 3: State of the prior art As stated in MPEP 2164.05(a), “[t]he state of the prior art is what one skilled in the art would have known, at the time the application was filed, about the subject matter to which the claimed invention pertains”. This factor weighs against enablement of the full scope. At the time the application was filed, the state of the art demonstrates that gem-hydrogenation of internal alkyne can coverts certain enyne substrates into a cyclic alkene, but major substrate and reaction scope limitations remain unresolved. Particularly, Biberger et al. (Angew. Chem. Int. Ed, 2020. Vol. 59: 18423–18429) reports the hydrogenative metathesis reaction shown below: PNG media_image6.png 399 459 media_image6.png Greyscale includes several serious limitations: (i) only enynes with a steering -OR substituent (R = methyl is representative) at the propargylic position were found to be adequate substrates; (ii) even amongst this class of compounds, only tertiary propargyl alcohol derivatives led to good yields; (iii) the alkene site of the substrate must be trisubstituted; (iv) for the propensity of the [Cp*Ru] fragment to engage in η6-binding with arenes, compounds containing (electron rich) aromatic rings basically failed to react under the standard conditions; (iv) because the metathetic ring closure needs to outperform the facile transformation of the carbene intermediate into the E-alkene, hydrogenative metathesis is essentially limited to the formation of five-membered rings (see e.g., p. 18424, left column, 1st paragraph). Additionally, Fürstner et al. (J. Am. Chem. Soc., 2019. Vol. 141: 11−24) reports the PHIP and DFT data suggest that the degree of carbene formation during the gem-hydrogenation of internal alkynes is substrate dependent; polar substituents in vicinity to the reacting triple bond (i) favor this pathway by lowering the barrier, (ii) largely determines the stability of the resulting carbene, and (iii) exert a directing effect and hence allow the site of carbene formation to be controlled (see e.g., p. 15, left column, 2nd last paragraph). Specifically, Fürstner et al. reports lateral -OR groups, such as -OMe and OH group, can stabilize the reactive carbene functionality (see e.g., p. 15, left column, last paragraph) whereas carbonyl groups seem to exert a less pronounced steering effect (see e.g., p. 15, right column, line 8-9). The state of the art also demonstrates that catalytic hydrogenation in over a century of intense research does not know of any other catalyst besides [Cp*Ru] catalyst that instigates this type of transformation. Particularly, Biberger et al. (Angew. Chem. Int. Ed, 2020. Vol. 59: 18423–18429) discussed a small set of precatalysts was screened during hit finding, and outlines three specific design principles for alternative catalyst: (1) up to three binding sites preferentially in a facial array for proper upload of substrate and H2; (2) careful balancing of the electron density at the central metal, and at the same time; and (3) the ligand sphere should push electron density into the hydrides to facilitate attack onto the co-ligated p-system (see e.g., p. 18424, right column, 2nd paragraph). In other words, the design of Ru catalyst for gem-hydrogenation requires careful optimization, including balancing electron density and managing binding sites by considering the steric and coordination. The state of the art also demonstrates that certain catalysts only operate in certain organic solvent and fails in others. Particularly, Biberger et al. (Angew. Chem. Int. Ed, 2020. Vol. 59: 18423–18429) reports [Cp*Ru] catalyst operates best in chlorinated media 1,2-Dichloroethane, and toluene (see e.g., p. 18425, left column, line 19-20); and Johansson et al. (J Am Chem Soc, 2008. Vol. 130(28): 8923-8930) reports the use of polar solvent, such as dimethyl sulfoxide (DMSO), is problematic in a typical ruthenium-catalyzed azide alkyne cycloaddition due to its ability to act as ligand to ruthenium, and protic solvents are not suitable due to low yields and a high degree of byproduct formation (see e.g., p. 14731, left column, last paragraph to right column, line 2). Although the hydrogenative metathesis reaction taught by Biberger et al. is not identical to the one instantly claimed, these processes of converting an enyne substrate into a cyclic alkene both belong to the same art-recognized filed of gem-hydrogenation reaction of internal alkynes. The teachings of Biberger et al. are not relied upon to establish non-enablement by itself; Rather, these references cited above are relied collectively as evidenced that within the same concept of gem-hydrogenation reaction or ruthenium-catalyzed reaction, a successful conversion of an enyne substrate into a cyclic alkene involves careful substituent selection on the substrate, Ru-catalyst and organic solvent altogether. While the art reflects that certain internal alkynes can successfully undergo gem-hydrogenation, the state of the art also demonstrates said gem-hydrogenation process requires specific electronic and steric conditions, including the presence of polar substituent -OR (also known as steering group) near the triple bond, as well as specific [Cp*Ru]based-catalyst with careful balancing of electron density at the central metal, the use of particular aprotic polar organic solvent in order to successfully arrive at the corresponding cyclic alkene. In view of the foregoing, the state of the art does not establish a generally applicable rule by which a skilled artisan could select arbitrary combination of variables within the present Markush definition and use it with an arbitrary species of Ru catalyst and organic solvent to performed gem-hydrogenation reaction, and then reasonably predict that it would successfully obtained an end product, including those with various ring systems such as bridge and spiro rings, especially armed with an understanding that there is a massive kinetic bias toward forming 5-membered ring, and compounds containing aromatic rings often failed to react under the standard conditions. Factor 4: Level of ordinary skill This factor favors Applicant to a degree but does not outweigh the remaining factors. A person of ordinary skill in the art would likely possess substantial training to conduct experiments in the field of medicinal chemistry, synthetic organic chemistry, and chemical biology. Such a person would know conventional synthetic transformation and would be capable of: preparing many analogs within the claimed formulas; selecting protecting groups; modifying synthetic routes; and analyzing structure-activity relationship data. The high level of skill would reduce the difficulty of making and testing individual compounds; However, enablement is not evaluated soley on whether conducting experiment is technically familiar. A skilled artisan’s ability to conduct routine synthesis and screening does not supply the missing predictive guidance concerning which of the extremely numerous claimed combinations will lead to a successful reaction. High skill may make a research program feasible, but it does not necessarily make the scope enabled where the artisan must discover operable species through extensive trial-and-error screening. Thus, this factor provides some support for enablement but does not resolve the breadth and predictability concerns. Factor 5: Predictability or unpredictability of the art Lastly, the state of the art is highly unpredictable. Optimization of gem-hydrogenation of internal alkynes was governed by experimentally determined factors, including mechanistic studies on substrate variations and the propargylic steering groups. A successful gem-hydrogenation reaction of preparing the compounds of formula (II), encompassing those with broad structural variation, could not reliably be predicted solely from the reaction scheme, because numerous factors such as steric hindrance, electronic density and functional group of substrates, the design of Ru-catalyst, and the selection of organic solvent can cause a gem-hydrogenation reaction to fail. Accordingly, one of ordinary skill in the art would not reasonably predict that arbitrary combinations of the numerous independently variable Markush substituents recited in the claims would lead to a successful reaction without experimental verification. Factor 6: Amount of direction or guidance in the specification This factor weighs against enablement of the full scope. While the specification provides substantial direction concerning: the generic formulae; lists of permitted substituents classes; list of permitted solvents; list of permitted Ru-catalyst; synthetic procedures for numerous compounds. This is meaningful guidance and supports enablement of certain exemplified compounds and closely related analogs. The specification, however, does not provide a sufficiently general predictive rule identifying which combinations across the claimed scope will remain operative for obtaining the corresponding cyclic alkene. Factor 7: Existence of working examples This factor favors Applicant to a degree, but only for preparing the chemical region represented by the examples. In the present case, the specification as-filed expressly disclosed the representative procedure of preparing certain compounds that fall within the claimed scope of Formula (II) via the hydrogenative C-H insertion reactions (on page 29 to page 37 of the specification). Thus, the working examples prove that the gem-hydrogenation process works to produce the intended compound. The exemplified compounds embraced by the instant claims are concentrated in selected families and do not systemically traverse all materially different alternatives and combinations encompassed by the claims. The working examples therefore weigh in Applicant’s favor to a degree, but their evidentiary weight is limited by the breadth and structural diversity of the untested claimed scope. Factor 8: Quantity of experimentation required This factor weighs strongly against enablement. To practice the full scope of process for C-H insertion by gem-hydrogenation of an internal alkyne, a skilled artisan would have to undertake, across the untested portion of the genus: selection of candidate combinations among numerous R1-R6 and Q to arrive compounds of Formula (I)-(II); candidate combinations of Rcap1-Rcp5, L and X to arrive at a Ru-catalyst; and organic solvent to be employed for the gem-hydrogenation process; analysis of failed and successful end product; and repetition of that process to determine operable parameters. The individual synthetic may be conventional. Nevertheless, the required combination is not merely confirmatory because the specification does not permit a skill artisan in advance which claimed combinations will be operative. Biberger et al. illustrates the nature of the required effort, the author performs precatalyst screening for formal gem-hydrogenation reactions of internal alkynes and optimizing reaction parameters, including adjusting a balance between electronic/steric ligand properties and temperatures, to successfully obtain the corresponding cyclic alkane. The task left by the present disclosure is therefore not simply to reproduce a disclosed procedure a reasonable number of times. It is to conduct an empirical research program across exceptionally broad multidimensional genus to confirm that the reaction can successfully obtain the intended product. The amount of such experimentation considered together with the absence of predictive guidance is undue. Conclusion A skilled artisan therefore would not be able, based upon the specification and ordinary knowledge alone, to make and use the full scope of the process claims without undertaking an extensive research program. Accordingly, the experimentation required is not merely routine confirmation of predictable results. It constitutes undue experimentation directed to discovering which members of the claimed genus are operative. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2-4 and 9-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 14, the phrase "such as", see e.g., “tetramer thereof such as [Cp*RuCl]4”, renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d); the claim repeatedly uses the terms “or” more than once within the same sentence, and it is hard to distinguish which limitation is supposed to be group together. For instance, the claim recites R5 and R6 of its formula is independently selected from the list shown below: “ PNG media_image7.png 183 618 media_image7.png Greyscale ”, and the term “(C1 to C12) alkyl” is repeated twice and separated by a coordinating conjunction “or”, it is not clear if the second recited “(C1 to C12) alkyl” in the phrase of “(C1 to C12) alkyl or hetero(C1 to C12) alkyl” is supposed to be group together with NRN1RN2, such that the “(C1 to C12) alkyl or hetero(C1 to C12) alkyl” is one of the the alternated RN2 groups; or said “(C1 to C12) alkyl or hetero(C1 to C12) alkyl” is another alternated R5 and R6 groups, and for that instance, it is not clear if the second recited “(C1 to C12) alkyl” is structurally different than the first recited (C1 to C12) alkyl; the recitation of “O or NRN in the ring” in the phrase of “if Q represents CH2, CH(C1 to C12 alkyl), or C(C1 to C12 alkyl)2, R4 and R5 each independently represent (C1 to C12)alkyl or hetero(C1 to C12)alkyl and form a ring system with each other with O or NRN in the ring” renders the claim indefinite, because it is not clear what is the ring being referred to therein. Please note the R4 and R5 of its formula refers to substituents shown below (see shaded): PNG media_image8.png 101 129 media_image8.png Greyscale . While the claim set forth the Q of its Formula (I) and (II) can be O or NRN, the conditional limitation noted above specifically limits Q to a narrow list that excludes O and NRN; this, it is not clear if the “O or NRN” in the ring is (a) referring to the “hetero(C1 to C12)alkyl” of R4 or R5; (b) referring to the Q portion; or other portions of the claimed structure. The recitation of “wherein the Ru catalyst is represented by the Formula (III)” is presented after the limitation of that recites “with the proviso that, if Q represents CH2, CH(C1 to C12 alkyl), or C(C1 to C12 alkyl)2…”, and that also renders the claim indefinite because it is not clear if this limitation drawn to the Ru catalyst is supposed to be conditional such that the limitation only applies when Q is CH2, CH(C1 to C12 alkyl), or C(C1 to C12 alkyl)2; or the limitation is applicable to all instance, including the instance that Q is O or NRN. The lack of clarity renders the claim indefinite, because one cannot reasonably determine which interpretation applies with reasonable certainty. The claim recites “RH” in the phrase of “ORH or NRH2” but fails to set forth what it is; therefore, it is not clear what is “RH”, such omission amounting to a gap between the structural elements. Each of these issues noted above renders the metes and bounds of the structural limitations unascertainable. Accordingly, claims 2-4 and 9-13 are rejected based on their dependency on a rejected base claim. Regarding claim 2, the claim recites the term “further common readily dissociating dative ligands known in the art” that appears to be relative term which renders the claim indefinite. The term “further common readily dissociating dative ligands known in the art” is not defined by the claim nor the specification, it is not clear which is considered a common or uncommon readily dissociating dative ligands as this depends on the context and the knowledge of the person using it; and it is also not clear which is considered a known and unknown readily dissociating dative ligands because what is considered “known” changes over time because information evolves. Therefore, the metes and bounds of the Ru-catalyst cannot be determined. In order to advance prosecution, the claim is reasonably construed in view of the elected Ru-catalyst, i.e., [Cp*RuCl]4. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Regarding claim 2, the recitation of “wherein the Ru-catalyst is selected from from COD, NBD, (C1 to C12 alkyl)CN, or (C1 to C12 alkyl)2O, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, substituted pyridines, η-arenes, H2 and further common readily dissociating dative ligands known in the art” fails to further limit the Ru-catalyst set forth in claim 14. Particularly, claim 14 recites “the Ru catalyst is represented by the formula (III) PNG media_image9.png 209 203 media_image9.png Greyscale ”; However, instant claim 2 includes Ru catalysts that do not fall within the scope of said formula (III). For example, H2 and tetrahydropyran are not compounds of formula (III). Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chihyi Lee whose telephone number is (571)270-0663. The examiner can normally be reached Monday - Friday 8:30 am - 5:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached at (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHIHYI LEE/Examiner, Art Unit 1628 /JEAN P CORNET/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Jun 14, 2024
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673950
Spiros and Related Analogs for Inhibiting YAP/TAZ-TEAD
3y 6m to grant Granted Jul 07, 2026
Patent 12576048
ANTI-CANCER ACTIVITY OF ADAMANTANE DERIVATIVES
4y 9m to grant Granted Mar 17, 2026
Patent 12551478
QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY
4y 10m to grant Granted Feb 17, 2026
Patent 12534451
SMALL MOLECULE MODULATORS OF PANK
4y 4m to grant Granted Jan 27, 2026
Patent 12522590
Brefeldin A Derivatives, Preparation Method and Use thereof
4y 4m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
34%
Grant Probability
96%
With Interview (+61.9%)
3y 7m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 88 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month